在I期临床试验病房接受治疗的晚期间皮瘤患者的临床结局与预后因素
该回顾性研究纳入2003年9月至2015年11月间38项I期试验中的65例晚期复发恶性间皮瘤患者,中位无进展生存期2.5个月,中位总生存期8个月;基于中性粒细胞与淋巴细胞比值大于3、超过两个疾病部位及白蛋白低于35三个因素建立m-RPS,A组(m-RPS 0-1,n=35)中位总生存期13.4个月 vs B组(m-RPS 2-3,n=30)4.0个月(P<0.0001)。
要点
- 65例晚期恶性间皮瘤患者中,4例(6%)达RECIST部分缓解,26例(40%)达RECIST疾病稳定超过3个月。
- m-RPS由中性粒细胞与淋巴细胞比值大于3、超过两个疾病部位、白蛋白低于35三个因素组成,每项计1分。
- A组(m-RPS 0-1,n=35)中位总生存期13.4个月 vs B组(m-RPS 2-3,n=30)4.0个月(P<0.0001)。
核心结论
- I期临床试验治疗在晚期恶性间皮瘤患者中耐受良好,并可见早期抗肿瘤活性信号。
- m-RPS是评估恶性间皮瘤患者是否适合参加I期试验的有用工具,作者认为应现在进行前瞻性验证。
研究设计与样本
- 回顾性研究,纳入2003年9月至2015年11月间参加38项I期试验的65例晚期恶性间皮瘤患者。
- 采用单因素和多因素分析建立m-RPS,疗效评估包括缓解率、中位总生存期和无进展生存期。
主要发现
- 中位无进展生存期为2.5个月(95%CI 2.0-3.1个月),中位总生存期为8个月(95%CI 5.6-9.8个月)。
- 4例(6%)患者达RECIST部分缓解,26例(40%)患者达RECIST疾病稳定超过3个月。
- A组(m-RPS 0-1,n=35)中位总生存期13.4个月(95%CI 8.5-21.6) vs B组(m-RPS 2-3,n=30)4.0个月(95%CI 2.9-7.1,P<0.0001)。
- 56例(86%)患者发生G1-2毒性,18例(28%)患者发生可逆的G3-4毒性;仅10例(15%)患者因毒性中止I期试验。
关键数值与推荐
- m-RPS包含三个预后因素:中性粒细胞与淋巴细胞比值大于3、存在超过两个疾病部位(包括淋巴结作为单个疾病部位)、白蛋白水平低于35,每项计1分。
- A组为m-RPS 0-1分(n=35),B组为m-RPS 2-3分(n=30)。
临床怎么用
- 作者认为m-RPS是评估恶性间皮瘤患者是否适合参加I期试验的有用工具,并应现在进行前瞻性验证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We have previously reported a prognostic score for patients in phase I trials in the Drug Development Unit, treated at the Royal Marsden Hospital (RPS). The RPS is an objective tool used in patient selection for phase I trials based on albumin, number of disease sites and LDH. Patients with mesothelioma are often selected for phase I trials as the disease remains localised for long periods of time. We have now reviewed the clinical outcomes of patients with relapsed malignant mesothelioma (MM) and propose a specific mesothelioma prognostic score (m-RPS) that can help identify patients who are most likely to benefit from early referral. METHODS: Patients who participated in 38 phase I trials between September 2003 and November 2015 were included in the analysis. Efficacy was assessed by response rate, median overall survival (OS) and progression-free survival (PFS). Univariate (UVA) and multivariate analyses (MVA) were carried out to develop the m-RPS. RESULTS: A total of 65 patients with advanced MM were included in this retrospective study. The PFS was 2.5 months (95% confidence interval [CI] 2.0-3.1 months) and OS was 8 months (95% CI 5.6-9.8 months). A total of four (6%) patients had RECIST partial responses, whereas 26 (40%) patients had RECIST stable disease >3 months. The m-RPS was developed comprising of three different prognostic factors: a neutrophil: lymphocyte ratio greater than 3, the presence of more than two disease sites (including lymph nodes as a single site of disease) and albumin levels less than 35 from the MVA. Patients each received a score of 1 for the presence of each factor. Patients in group A (m-RPS 0-1; n = 35) had a median OS of 13.4 months (95% CI 8.5-21.6), whereas those in group B (m-RPS 2-3; n = 30) had a median OS of 4.0 months (95% CI 2.9-7.1, P < 0.0001). A total of 56 (86%) patients experienced G1-2 toxicities, whereas reversible G3-4 toxicities were observed in 18 (28%) patients. Only 10 (15%) patients discontinued phase I trials due to toxicity. CONCLUSIONS: Phase I clinical trial therapies were well tolerated with early signals of antitumour activity in advanced MM patients. The m-RPS is a useful tool to assess MM patient suitability for phase I trials and should now be prospectively validated.
引用
- Papadatos-Pastos D, Roda D, De Miguel Luken MJ, et al. Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. Eur J Cancer. 2017. PMID: 28214659. doi:10.1016/j.ejca.2016.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。